Clinical trials: Aspirin
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
The purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of Ticagrelor (AZD6140) compared with Clopidogrel, both given on top of low dose aspirin, in Asian/Japanese…
- Trial name
- NCT01294462
- Testing
- Ticagrelor, Clopidogrel, Acetylsalicylic acid ASA
- Where
- 87 sites in Japan, South Korea and 1 more
- Volunteers
- 801 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.
- Trial name
- NCT02786979
- Testing
- Beraprost, Aspirin
- Where
- 6 sites in China
- Volunteers
- 190 people
- Sponsor
- Astellas Pharma Inc
Platelet Inhibition
A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin
The primary hypothesis of this study is that concomitant multiple-dose administration of PN 400 does not interfere with the platelet inhibitory effects of enteric-coated low-dose aspirin (81 mg), as measured by serum thromboxane…
- Trial name
- NCT01094483
- Testing
- PN400, ASA
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Peripheral Artery Disease
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the…
- Trial name
- VOYAGER PAD (NCT02504216)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 532 sites in United States, Argentina and 32 more
- Volunteers
- 6,564 people
- Sponsor
- Bayer
Coronary Artery Disease
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination
The purpose of this study is to compare pharmacokinetics between fixed-dose combination and separate combination of clopidogrel 75mg/aspirin 100mg.
- Trial name
- NCT01663038
- Testing
- Clopidogrel, Fixed dose combination of clopidogrel/Aspirin, Aspirin
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Atrial Fibrillation
S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
Evaluate efficacy and safety of Indobufen v. Aspirin in preventing thromboembolic events in patients at high risk of CV events such as patients suffering from nonrheumatic atrial fibrillation.
- Trial name
- SIFA (NCT00244426)
- Testing
- indobufen, aspirin
- Where
- 132 sites in Italy
- Volunteers
- 1,372 people
- Sponsor
- Pfizer
Healthy
A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fed Condition
The study was conducted as an open label, balanced, randomised, two-treatment, two-period, two-sequence, single dose, crossover bioavailability study comparing acetaminophen extended release gelcaps 650 mg (containing…
- Trial name
- NCT01079078
- Testing
- Acetaminophen
- Where
- India
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Dyslipidemia
Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia
The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin extended-release (NER)-induced flushing in subjects with dyslipidemia.
- Trial name
- ASA EFFECTS (NCT00626392)
- Testing
- niacin extended-release (NER), aspirin (ASA)
- Where
- 26 sites in United States
- Volunteers
- 277 people
- Sponsor
- Abbott
Arteriosclerosis
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
RATIONALE: Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
- Trial name
- NCT00050817
- Testing
- clopidogrel (SR25990)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 15,603 people
- Sponsor
- Sanofi
Platelet Dysfunction Due to Aspirin Ingestion
AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction
To test the AggreGuide A-100 AA Assay's effectiveness for detecting aspirin induced platelet dysfunction.
- Trial name
- NCT01915407
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Aggredyne, Inc.
Coronary Heart Disease, Cardiac Dysfunction
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
A randomized controlled trial was conducted to evaluate the efficacy and safety of Yangxinshi tablets in improving the condition of patients with coronary heart disease complicated by cardiac dysfunction.
- Trial name
- HEARTPOWER (NCT07110415)
- Testing
- Yangxinshi tablet, Blank control
- Where
- 96 sites in China
- Volunteers
- 2,708 people
- Sponsor
- SPH Qingdao Growful Pharmacetical Co.,Ltd
Healthy
Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects
The purpose of this study is to compare the safety, pharmacokinetics, and pharmacodynamic effects of aspirin administered intravenously with aspirin administered orally.
- Trial name
- NCT05166096
- Testing
- Rho-11, aspirin 325mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Rhoshan Pharmaceuticals Inc
Polycythemia Vera (PV)
A Study to Evaluate P1101 in Japanese PV Patients
This is a Phase 3 single arm study to investigate efficacy and safety of P1101's rapid titration for adult Japanese patients with PV.
- Trial name
- NCT06002490
- Testing
- P1101, Low-dose aspirin, Phlebotomy
- Where
- 6 sites in Japan
- Volunteers
- 21 people
- Sponsor
- PharmaEssentia Japan K.K.
Acute Coronary Syndromes
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
To investigate how platelets recover to normal function in subjects who have symptoms of a heart attack or unstable angina and who get a loading dose of prasugrel or clopidogrel for planned coronary angiography.
- Trial name
- NCT01107899
- Testing
- clopidogrel, prasugrel
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Nonfatal Myocardial Infarction, Coronary Death
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and…
- Trial name
- NCT01360047
- Where
- Spain
- Volunteers
- 39,513 people
- Sponsor
- AstraZeneca
Self-administered Questionnaire to Patients
Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France
The purpose of this study is to assess in general population low-dose aspirin and gastroprotective agent compliance and reasons for bad compliance
- Trial name
- NCT01238809
- Volunteers
- 7,300 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Myocardial Ischemia, Acute Coronary Syndrome
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention…
- Trial name
- NCT00089895
- Testing
- Eptifibatide (Integrilin)
- Volunteers
- 9,406 people
- Sponsor
- Organon and Co
Polycythemia Vera (PV)
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.
- Trial name
- NCT04655092
- Testing
- P1101 (Ropeginterferon alfa-2b)
- Where
- 6 sites in Japan
- Volunteers
- 67 people
- Sponsor
- PharmaEssentia Japan K.K.
Acute Coronary Syndrome
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12…
- Trial name
- GEMINI ACS 1 (NCT02293395)
- Testing
- Acetylsalicylic acid, Rivaroxaban, Clopidogrel
- Where
- 259 sites in United States, Argentina and 18 more
- Volunteers
- 3,037 people
- Sponsor
- Janssen Research & Development, LLC